Novartis COPD

A New Year's resolution for COPD Novarti

For the first time, COPD treatment will now only be guided by the everyday symptoms and flare-up (exacerbation) risk faced by people living with the condition. Lung function tests measuring how much air you can breathe out in one forced breath, such as spirometry, will still be essential to confirm a COPD diagnosis and to assess prognosis over time, but won't guide the treatment recommendations Getting diagnosed with a chronic disease can be scary and confusing - and the impact on friends and family members, especially children, is often overlooked. Chronic obstructive pulmonary disease (COPD) is an umbrella term used to describe a collection of lung diseases including chronic bronchitis and emphysema

COPD ist eine langsam verlaufende und voranschreitende Erkrankung der Lunge. 1 Es kommt zu einer Verengung der Bronchien (=chronisch obstruktive Bronchitis) und häufig zu einer Überblähung der Lunge (= Lungenemphysem) The Novartis COPD portfolio includes QVA149/Ultibro Breezhaler (indacaterol/glycopyrronium bromide), NVA237/Seebri Breezhaler (glycopyrronium bromide) and Onbrez® Breezhaler®/Arcapta®Neohaler® (indacaterol inhalation powder), which are all indicated as maintenance treatments for COPD patients

Novartis, Medikidz® and the COPD Foundation: a partnership

Novartis COPD Portfolio Backgrounder Novartis is committed to addressing the unmet medical needs of patients with chronic obstructive pulmonary disease (COPD) and improving their quality of life by providing innovative medicines and devices. COPD COPD is a progressive, life-threatening lung disease causing disability and death affectin The Novartis US COPD portfolio includes Utibron Neohaler, Seebri Neohaler and Arcapta Neohaler, which are all indicated as maintenance treatments for COPD patients and use transparent capsules to.

With near-real time data capture from the patient and the connected device, Novartis aims to improve medication adherence and ultimately health outcomes for COPD patients. Novartis plans to launch the new connected Breezhaler in 2019 following manufacturing, testing and regulatory approvals. About Qualcomm Incorporate 12 Aug AUSBIZ VIDEO: Novartis commercial deal and COPD application of XV Technology. Posted at 14:53h in News by Chelsea Cunningham Novartis launches COPD inhalers in China. March 22, 2019 By Sarah Faulkner. Novartis (NYSE: NVS) has launched its Ultibro Breezhaler and Seebri Breezhaler in China for the treatment of chronic obstructive pulmonary disease. The Ultibro Breezhaler system is a once-daily fixed-dose combination of indacaterol and glycopyrronium bromide

Looking at these opportunities in the COPD market, Novartis is focusing on deepening its footprint in this market. The company's COPD drugs have reported superior efficacy and safety in treatment. Study Design. A Multi-center, Randomized, Double-blind, Double-dummy, Active Controlled, 2-period Cross-over Study to Assess the Efficacy, Safety and Tolerability of Indacaterol Maleate/Glycopyrronium Bromide Compared to Umeclidinium Bromide/Vilanterol in COPD Patients With Moderate to Severe Airflow Limitation COPD makes it difficult to breathe, with symptoms that have a destructive impact on patients' function (i.e. activity limitation, decreased mobility) and quality of life. About Novartis. Novartis provides innovative healthcare solutions that address the evolving needs of patients and societies Maintenance inhaled treatment of chronic obstructive pulmonary disease (COPD) is based on long-acting β 2-agonist (LABA) and/or long-acting muscarinic antagonists (LAMA) and LABA/inhaled corticosteroid (ICS) [].Despite treatment, most of the patients remain symptomatic, requiring a change in therapy [].A once-daily (q.d.) combination of indacaterol and glycopyrronium (IND/GLY) was effective. Novartis International AG / Novartis' Ultibro® Breezhaler® consistently more effective than Seretide®* inreducing COPD flare-ups across different patient groups . Processed and transmitted by Nasdaq Corporate Solutions.The issuer is solely respo

Novartis is committed to addressing the unmet medical needs of COPD patients and improving their quality of life by providing innovative medicines and devices. SPARK is one of 10 studies investigating QVA149 for the treatment of COPD in the IGNITE Phase III clinical trial program, which involves more than 7,000 patients across 42 countries This video aims to illustrate what it is like to live with Chronic Obstructive Pulmonary disease (COPD) while undertaking everyday activities via a split scr..

COPD-Patienten mit Lungenüberblähung haben ein erhöhtes Risiko für kardiovaskuläre Komorbiditäten. Wie der Schweizer Pharmakonzern Novartis nun mitteilt, soll das Kombinationsarzneimittel. Lung function of COPD patients improved with Ultibro Breezhaler, Novartis has announced positive results from the FLASH study. Recommended. The Future of QA/QC for Complex Biologics: Listen to thought-provoking presentations from industry experts and leaders from around the world in our virtual summit Patient-Reported Outcomes (PROs) in COPD Clinical Trials: Trends and Gaps. Int J Chron Obstruct Pulmon Dis. 2020 Jul 23;15:1789-1800. doi: 10.2147/COPD.S235845. eCollection 2020 Novartis files COPD combo in US QVA149 combines long-acting beta agonist with long-acting muscarinic antagonist Armed with a fresh set of phase III data, Novartis has finally submitted its chronic obstructive pulmonary disease (COPD) therapy QVA149 for marketing in the US

Chronisch obstruktive Lungenerkrankung Novartis Austri

  1. COPD is the seventh leading cause of death in the Philippines. 6 Novartis fully supports the PCCP in implementing the BREATHE initiative and achieving our shared goal of making more Filipinos aware of COPD and easing its heavy disease burden in the country, said Ms. Cheryl Maley, President & Managing Director, Novartis Healthcare Philippines
  2. A current hot topic in COPD is that two fixed triple combinations of an inhaled corticosteroid (ICS), a long-acting β2-agonist (LABA) and a long-acting muscarinic antagonist (LAMA) in a single inhaler have become available for patients with COPD, and a third triple therapy is in advanced development with the first large randomised clinical trial (RCT) recently published in Lancet.
  3. Novartis International AG / FLAME study shows superiority of Novartis' Ultibro® Breezhaler® over Seretide®in reducing COPD exacerbations . Processed and transmitted by NASDAQ OMX Corporate Solutions.The issuer is solely responsible for the content of this announcement
  4. Novartis COPD strong data supports LAMA/LABA combos. Novartis has been presenting impressive data on its new chronic obstructive pulmonary disease drugs, most notably on its combination treatment QVA149. At the European Respiratory Society meeting in Vienna, the Swiss major gave information on three new studies of QVA149, which combines its own.

Welcome to the Novartis portal for UK healthcare professionals (HCPs) and other relevant decision makers *, where you can find promotional information about Novartis products, therapy area materials and professional resources. *Other relevant decision makers particularly includes those with an NHS role who could influence in any way the administration, consumption, prescription, purchase. Study Description. This is a Phase 2 study in patients with chronic obstructive pulmonary disease (COPD) to assess the efficacy, pharmacodynamics (PD), pharmacokinetics (PK), and safety of two dose levels of CSJ117 in comparison to placebo. For this, the impact of CSJ117 on disease symptom burden and lung function will be explored Novartis says almost 27 million Americans have COPD, making it the third leading cause of death in the U.S. Novartis hopes to grab a large share of a market expected to reach $14 billion by 2018 COPD. Clinical resources. Access clinical information on COPD and download other useful resources for your practice Show More Patients with a history of cancer and 5 years or more disease free survival time may be included in the study by agreement with Novartis Medical Monitor on a case-by-case basis. Patients who develop a COPD exacerbation that required treatment with antibiotics and/or oral corticosteroids and/or hospitalization during screening

A Safety, Tolerability and Efficacy Study With QBW251 in COPD Patients With QBW251 - Full Text View The annual rate of severe COPD exacerbations was 0.15 (95% CI, 0.11 to 0.19) in the indacaterol-glycopyrronium group and 0.17 (95% CI, 0.13 to 0.22) in the salmeterol-fluticasone group (rate. Basel, April 25, 2014 - Novartis announced today top-line results from the Phase IV INSTEAD switch study in patients with chronic obstructive pulmonary disease (COPD), which met its primary objective COPD is predicted to be the third leading cause of death in the world by 2020 [4] Basel, April 2, 2012 - The first three Novartis QVA149 Phase III studies in the treatment of chronic obstructive. Novartis Medizinischer InfoService Kennwort COPD Roonstraße 25, 90429 Nürnberg Tel.: 08 00-54 55 000 (kostenlos) Servicezeiten: Montag-Freitag von 8-18 Uhr Email: infoservice.novartis@novartis.co

Novartis announces two positive US phase III programs in

  1. Novartis' COPD drugs backed for EU approval. Novartis' new chronic obstructive pulmonary disorder therapies Ultibro Breezhaler and Xoterna Breezhaler are a massive step closer to winning European approval after an endorsement by the EMA's Committee for Medicinal Products for Human Use. Ultibro Breezhaler, which is also known as QVA149, is the.
  2. Novartis Pharma AG. Basel, SWITZERLAND. New data showed switching moderate-to-severe, symptomatic COPD patients from Seretide® * to Ultibro® Breezhaler® improved lung function and was well.
  3. Advisors to the US regulator have voted to recommend approval of Novartis' chronic obstructive pulmonary disease drug indacaterol but only at the lower of the two doses proposed by the Swiss drugmaker. - News - PharmaTime
  4. COPD is an umbrella term for a group of diseases including emphysema, That includes four kinds distributed by Novartis, called Breezhalers,.
  5. Novartis International AG / Novartis QVA149 Phase III COPD studies meet primary endpoints . Processed and transmitted by ONE. The issuer is solely responsible for the content of this... | September 3, 202
  6. Sunovion, Novartis ink licensing deal for inhaled COPD drugs. Novartis (NYSE: NVS) said today that it out-licensed its U.S. commercial rights for 3 chronic obstructive pulmonary disease drugs to Sunovion Pharmaceuticals. Novartis will commercialize the Utibron Neohaler, Seebri Neohaler, and Arcapta Neohaler inhalation powders outside of the U.S
  7. QVA149 improved lung function, breathlessness and health-related quality of life in moderate-to-severe COPD patients, according to EXPEDITION trial results[1]-[7] ; GEM 1 & 2 studies showed NVA237 provided significant and clinically meaningful improvements in lung function in moderate-to-severe COPD patients[8],[9] ; In total, 26 Novartis abstracts presented at American Thoracic Society (ATS.

Novartis has now formulated glycopyrrolate as a dry powder formulation for inhalation use in COPD patients as a single entity product (subject of this NDA) and as a combination product with indacaterol (subject of NDA 207930 for Utibron Neohaler). Inhaled anticholinergics are widely available in the U.S. and worldwide for the treatment of COPD First COPD exacerbations starting between first dose and one day after last treatment are included. Cox regression model includes terms for treatment, baseline total symptom score, baseline COPD exacerbation history (i.e. number of COPD exacerbations during the past 12 months prior to study), smoking status at screening, ICS use at screening, airflow limitation severity, and region Pfizer says it plans to make Ultibro available in the UK in due course, where there are approximately three million COPD sufferers. Novartis will continue to be responsible for the manufacture, sales and distribution of both medicines, in addition to regulatory, pharmacovigilance and medical information commitments Despite the encouraging data versus its rivals, Novartis is breaking into a market dominated by its competitors in COPD and could do with some additional marketing muscle in some markets. To that end it signed an agreement with Pfizer last week to co-promote Ultibro and Seebri (glycopyrronium bromide) in the UK

Novartis and Qualcomm are to develop a 'smart' COPD inhaler to allow patients to digitally monitor their medication. The announcement follows similar plans by Novartis's rivals in the. De Volari app is ontworpen om u te helpen leven met COPD. Volari helpt u inzicht te krijgen in uw klachten en gewoonten in de loop van de tijd. Daarnaast geeft Volari eenvoudige adviezen en handvatten. In het leven gaat het om keuzes maken. Het is nooit te laat om voor iets nieuws te kiezen Novartis' Ultibro® Breezhaler® significantly improved COPD patients' lung function after direct switch from Seretide® Read full article November 27, 2017, 2:18 A Patients have told us about the tremendous impact their COPD can have on everyday activities, said Christi Shaw, US Country Head, President of Novartis Corporation and Novartis Pharmaceuticals. Hurst has received support to attend meeting, and payment for education and advisory work (personally and to his employer, UCL) from pharmaceutical companies that make medicines to treat COPD. M. Roman-Rodriguez reports personal fees and grants from AstraZeneca, Boehringer Ingelheim, GSK, Mundipharma, Novartis, Teva, and Trudell Medical International in the last 3 years

Video: Novartis sells US rights to 3 COPD drugs BioPharma Div

Medications | the lung association

n engl j med 374;23 nejm.orgJune 9, 2016 2223 Indacaterol-Glycopyrronium vs. Salmeterol-Fluticasone for COPD E xacerbations of chronic obstruc-tive pulmonary disease (COPD) are associ Novartis International AG / Novartis' INSTEAD study for Onbrez® Breezhaler® in patients with moderate COPD meets primary objective . Processed and transmitted by NASDAQ OMX Corporate... | August 21, 202 Treatment with Novartis' Ultibro Breezhaler significantly boosted lung and cardiac function in chronic obstructive pulmonary disease (COPD) patients with lung hyperinflation, trial findings show. Lung hyperinflation, a common occurrence in people with COPD, has been linked to impaired cardiac function and a worsening of COPD symptoms, especially breathlessness QVA149 improved lung function, breathlessness and health-related quality of life in moderate-to-severe COPD patients, according to EXPEDITION trial results[1]-[7] | July 7, 202 DOWNLOAD AND CHECK IN: Every day Volari wants to Check-In with you to ask you how you're feeling and what you're doing. 2. TRACK AND LEARN: Volari offers you an on-demand snapshot of your progress so you can spot trends in symptoms and habits over time. 3. REWARD AND SHARE: Volari rewards your progress so that you can share it with friends.

The Novartis COPD portfolio includes Onbrez ® Breezhaler ® / Arcapta ® Neohaler ® (indacaterol), Seebri ® Breezhaler ® (glycopyrronium bromide) and Ultibro ® Breezhaler ® (indacaterol / glycopyrronium bromide), which are all indicated as maintenance treatments for COPD patients Novartis' Ultibro® Breezhaler® consistently more effective than Seretide®* in reducing COPD flare-ups across different patient groups Read full article September 2, 2016, 10:16 P Novartis International AG / Novartis QVA149 Phase III study meets primary endpoint in reducing exacerbations in COPD patients, filing in EU and Japan by end of year . Processed and transmitted by... | September 9, 202 Subject: Novartis Submits NDA For COPD Drug In Japan Add a personalized message to your email. Cancel. Send. Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe. Sign In To Set a. Novartis first-in-class once-daily dual bronchodilator Ultibro Breezhaler (QVA149) achieves near simultaneous approval for COPD patients in Europe and Japan Read full article September 22, 2013.

Novartis' COPD combo show benefits in switching from

Ultibro Breezhaler has been studied in two main studies involving a total of 2,667 patients with COPD. While one study compared the effects of Ultibro Breezhaler with those of placebo (a dummy inhalation), or indacaterol or glycopyrronium alone, the other study compared Ultibro Breezhaler with fluticasone plus salmeterol, a standard treatment for COPD It can cause serious problems for people with COPD. So, do your best to avoid crowds during flu season. Consider getting a flu shot every year. And ask your provider about the pneumonia vaccine. 6) seek suPPort From others who have CoPD. See if your local hospital has a COPD support group. You can also find a very active COPD community online

COPD causes considerable health and economic burden worldwide, with incidence of the disease expected to continue to rise. Inhaled bronchodilators, such as long-acting muscarinic antagonists (LAMAs) and long-acting β 2-agonists (LABAs), are central to the maintenance treatment of patients with COPD.Clinical studies have demonstrated that combined LAMA + LABA therapies improve efficacy while. Minn Lung - Novartis COPD. My Local Study. February 28, 2020 · Minneapolis, MN · · Minneapolis, MN Novartis (NYSE:NVS) said today that a new analysis of its head-to-head Flame trial showed that inhaled corticosteroids may not be necessary in some chronic obstructive pulmonary disease patients with high blood eosiophil counts.. The data demonstrated that the company's Ultibro Breezhaler provided better or similar benefits compared to Seretide, an inhaled corticosteroid, in COPD patients.

Novartis data at ERS 2014 show once-daily Ultibro® Breezhaler® is superior in reducing COPD flare ups compared to Seretide®* Read full article September 7, 2014, 4:02 A 올린이: Komal 10월 24, 2021 COPD 약물 시장 2021 연구 및 임상 분석 - Pfizer, Novartis, GlaxoSmithKline, Merck, Abbott Laboratories, Boehringer Ingelheim 에 댓글 남기기 2021~2027년까지의 글로벌 COPD 약물 시장 규모 및 예측 은 비즈니스 전략가에게 유용한 통찰력 있는 데이터 소스입니다 Global COPD Drugs Scope and Market Size COPD Drugs market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global COPD Drugs market will be able to gain the upper hand as they use the report as a powerful resource

HCP Materials. Discover more about COPD and Breezhaler. HCP Materials Novartis files COPD combo in US. Armed with a fresh set of phase III data, Novartis has finally submitted its chronic obstructive pulmonary disease (COPD) therapy QVA149 for marketing in the US. The company confirmed today it filed applications QVA149 - a combination of long-acting beta agonist indacaterol and long-acting muscarinic antagonist. The burden of chronic obstructive pulmonary disease (COPD) is considerable, both socially and economically. Central to COPD management is the use of long-acting bronchodilators, which provide patients with optimal bronchodilation and improvements in symptoms. The once-daily, long-acting β2-agonist indacaterol, the long-acting muscarinic antagonist glycopyrronium, and the indacaterol. 0515COPD380726. The Volari app is designed to help you live with COPD. Volari helps you understand your symptoms and habits over time. Additionally Volari gives simple advice and handles. In life it comes to making choices. It's never too late to choose something new Sunovion Pharmaceuticals and Novartis have entered a commercialization agreement for three drugs approved by the U.S. Food and Drug Administration (FDA) indicated for the long-term, maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD).. Utibron Neohaler (indacaterol and glycopyrrolate) inhalation powder (27.5 mcg/15.6 mcg) and Seebri.

COPD - Die 10 wichtigsten Fakten | Leichter-atmen

Novartis Out-Licenses Three COPD Products in the US - Drug

Qualcomm Expands Collaboration with Novartis for Connected COPD Therapy. SAN DIEGO — January 5, 2016 — Qualcomm Incorporated (NASDAQ: QCOM) today announced that its subsidiary, Qualcomm Life, Inc., and Novartis are expanding their global connected therapy management collaboration. Novartis will leverage Qualcomm Life's connectivity. Novartis announced that the European Commission approved once-daily Ultibro Breezhaler (indacaterol 85 mcg/glycopyrronium 43 mcg) as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD). In addition, the Japanese Ministry of Health, Labor and Welfare (MHLW) approved once-daily Ultibro Inhalation Capsules (glycopyrronium. Background: Indacaterol is an inhaled, long-acting β(2)-agonist providing 24-h bronchodilation with once-daily dosing in patients with COPD. Methods: Subjects with moderate to severe COPD who completed a 26-week, randomized, double-blind study were eligible for enrollment in an extension, during which treatment with double-blind indacaterol, 150 or 300 μg once daily, or placebo was continued.

Sunovion has secured US rights to Novartis's respiratory inhalers, and will cash in on Novartis's FLAME data in COPD patients which recently helped change treatment guidelines Novartis offers prescription products to treat severe allergic asthma and chronic obstructive pulmonary disease (COPD). Xolair, and TABI, Onbez Breezhaler are the top products in this category. Neuroscience Science Treatment Category Novartis has taken a leap forward in rolling out its new chronic obstructive pulmonary disease (COPD) franchise with approvals for long-acting muscarinic antagonist (LAMA) Seebri in the EU and Japan. Seebri (glycopyrronium bromide) has been approved as a once-daily inhaled treatment for adults with COPD, and will join Novartis' long-acting beta.

Novartis' combo COPD inhaler cleared in EU - PMLiV

Therapeutic immunomodulation with a sublingual mucosal bacterial vaccine in adults with COPD reduced the number and length of exacerbations and antibiotic use, researchers reported at the European. Novartis AG Cheered by COPD Trial Results. Published: Sep 05, 2012. Frimley, UK, 3 September 2012 - Further data from the Novartis once-daily chronic obstructive pulmonary disease (COPD) clinical trial programmes were presented at the European Respiratory Society (ERS) Congress. Overall, Novartis presented 14 abstracts, including data from. Novartis' New Analyses Reinforce Ultibro Breezhaler Potential for COPD Patients Treated with Steroids By Drug Discovery Trends Editor | May 30, 2017 Further analyses of Novartis' head-to-head FLAME study suggest that inhaled corticosteroids (ICS) may not be needed in some chronic obstructive pulmonary disease (COPD) patients with high blood eosinophil (a type of white blood cell) counts Novartis' Ultibro® Breezhaler® improved lung function and COPD symptoms after direct switch from previous treatment 08 déc. 2016 01h15 HE | Source: Novartis Pharma AG Novartis Pharma A Ultibro Breezhaler 85microgram / 43microgram inhalation powder capsules with device (Novartis Pharmaceuticals UK Ltd) 10 capsule Type Dry powder inhaler (DPI) Medicine Stage 2, NICE COPD, exacerbations or persistent breathlessness and FEV1 50-79%. Prescribin

Novartis Pipeline Novarti

Purpose: The all-cause readmission rate within 30 days of index admissions for chronic obstructive pulmonary disease (COPD) was approximately 21% in the United States in 2008. This study aimed to examine patient and clinical characteristics predicting 30-day unplanned readmissions for an initial COPD hospitalization and to determine those predictors' importance New indication boost for Novartis COPD therapy. September 29, 2017 Latest News. Respiratory experts believe the regulatory approval of the first dual-bronchodilator for the reduction of COPD flare-ups will help reduce the use of inhaled corticosteroid (ICS) in a large number of patients. Novartis said the TGA has updated the indication for PBS.

Basel, April 2, 2012 - The first three Novartis QVA149 Phase III studies in the treatment of chronic obstructive pulmonary disease (COPD) all met their primary endpoints. The SHINE, BRIGHT and. Novartis has presented new data from chronic obstructive pulmonary disease (COPD) portfolio at the American Thoracic Society (ATS) International Conference in Philadelphia. In total, Novartis presented 34 respiratory abstracts, featuring latest findings from the IGNITE clinical trial program including BLAZE and SPARK studies, plus data from pooled GLOW1 and 2 studies

Novartis out-licenses three COPD products in the U

Novartis in Canada responds to COVID-19 with commitments in key areas. Our primary concern at Novartis remains the health and safety of our associates and patients globally, and it is Novartis focuses its business on three leading divisions on a global scale: pharmaceuticals, eye care and generics Novartis products treat and prevent a range of diseases and conditions from hypertension and cancer to cataracts and migraines. Our Process Scientific research drives innovation at Novartis. Our researchers work to push the boundaries of science for the benefit of patients Novartis is committed to addressing the unmet needs of COPD patients and improving their quality of life by providing innovative medicines and devices. QVA149 (indacaterol 110 mcg/glycopyrronium bromide 50 mcg) is an investigational inhaled, once-daily, fixed dose combination of the long acting beta2-agonist (LABA) indacaterol, and the long-acting muscarinic antagonist (LAMA. Frequent Symptoms . Noticeable COPD symptoms may not show up until the disease is advanced and you've already incurred lung damage.   Common symptoms in early COPD, should they occur, include shortness of breath, wheezing, cough, fatigue, phlegm production, and chronic respiratory infections, which can range from mild to very severe depending on the stage of the disease Novartis data at ERS shows efficacy of once-daily COPD portfolio versus comparators, further establishes dual-bronchodilator QVA149 September 03, 2012 01:15 ET | Source: NOVARTIS FINANCE S.A.

Ultibro Breezhaler 85microgram/43microgram inhalationCOPD: Utibron Neohaler Now Available in US | RTNew LABA inhaler for COPD | MIMS onlineLung function of COPD patients improved with Ultibro

Bloomberg the Company & Its Products The Company & its Products Bloomberg Terminal Demo Request Bloomberg Anywhere Remote Login Bloomberg Anywhere Login Bloomberg Customer Support Customer Suppor Treatment with Novartis' Ultibro® Breezhaler® improved cardiac function in COPD patients with lung hyperinflation 22 févr. 2018 01h15 HE | Source: Novartis Pharma AG Novartis Pharma AG Basel. Novartis will leverage Qualcomm Life's connectivity solutions to power its next-generation connected Breezhaler™, the inhaler for its Chronic Obstructive Pulmonary Disease (COPD) portfolio